Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease

Okada, Morihito; Nishio, Wataru; Sakurai, Toshihiko; Uchino, Kenji; Yuki, Tsuyoshi; Nakagawa, Akio; Tsubota, Noriaki

doi:10.1016/j.athoracsur.2004.02.009

Cited by 149 publications

(140 citation statements)

References 9 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…Although CEA was often falsely elevated in smokers and in patients with restrictive or obstructive pulmonary disease (18)(19)(20), abnormally elevated CEA levels were reported in 30-70% of patients with NSCLC and were most frequently observed in patients with adenocarcinoma and advanced stage carcinoma (21). In addition, several studies have shown that h-CEA is a potential marker of poor prognosis in NSCLC regardless of treatment (7,21).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

Jung

Kim

Lee

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The prognostic and predictive value of pre-treatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib. Pre-treatment CEA and CYFRA 21-1 levels were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. High CEA levels (h-CEA) were significantly associated with females, patients with adenocarcinoma and non-smokers. Low CYFRA 21-1 levels (l-CYFRA 21-1) were significantly associated with a good performance status (ECOG PS 0-

show abstract

Section: Discussionmentioning

confidence: 99%

“…Several (6)(7)(8)(9)(10). According to recent reports, CEA and CYFRA 21-1 were significant predictors of sensitivity and survival in patients treated with gefitinib (11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

Jung

Kim

Lee

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…The prognosis of advanced NSCLC after failure of second-or third-line treatment is generally only weeks to months (Okada et al, 2004). For effective antitumor results, some patients should alternate the treatment program.…”

Section: Discussionmentioning

confidence: 99%

“…Tumor markers may be used to evaluate their effect. The level of carcinoembryonic antigen (CEA) predicts tumor response well in patients with advanced NSCLC treated with gefitinib or erlotinib (Parra et al, 2004;Okada et al, 2004;Mok et al, 2009). Here, we describe 2 Chinese patients with advanced NSCLC treated with gefitinib or erlotinib in terms of long-term survival.…”

Section: Introductionmentioning

confidence: 99%

Case Report Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment

Zhang¹,

Tan²,

Zhang³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced nonsmall-cell lung cancer (NSCLC), but the median survival of patients is short. Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. The first patient was alive at 8 years with alternative conventional chemotherapy and gefitinib, and the second patient was alive at long-term follow-up with conventional chemotherapy and gefitinib or erlotinib. Gefitinib, erlotinib, and conventional chemotherapy can be combined for satisfactory therapy for NSCLC.

show abstract

“…Recent studies have indicated that elevated S-CEA are associated with more advanced disease and with poor survival (12,(31)(32)(33)(34)(35). Okada et al (34) measured S-CEA levels before and after surgery in 1000 consecutive patients with clinical stage I NSCLC who underwent resection of tumor.…”

Section: Distant Metastasesmentioning

confidence: 99%

Serum Carcinoembryonic Antigen Level as a Predictive Marker for Distant Metastasis in Non-Small Cell Lung Cancer

et al. 2007

View full text Add to dashboard Cite

Aim: Elevated serum CEA (S-CEA) levels are sometimes attributable to the production of CEA by malignant cells, and in turn, the antigen itself can enhance the metastatic potential of malignant cells. We investigated the predictive role of S-CEA level for distant metastasis in nonsmall cell lung cancer (NSCLC).Methods: Consecutive 116 NSCLC patients referred to our department were retrospectively investigated. S-CEA levels was compared according to age, gender, smoking habits, histological type, distant metastases and clinical disease stage in all patients.Results: There were no significant relationship between S-CEA level and age, gender and smoking habits. There was significant difference in S-CEA level between M0 and M1 patients (p<0.001). S-CEA levels were not significantly different between symptomatic and silent metastases NSCLC patients (p=0.103). We could not find significant differences in S-CEA levels between T1-2 and T3-4 (p=0.141), N0-1 and N2-3 (p=0.672). In NSCLC, the area under the ROC curve was 0.728 (p<0.001), S-CEA threshold of 6.4 ng/mL has predictive sensitivity and specificity, for distant metastases as 69.8% and 73.0% respectively. In multivariate analysis including age, gender, smoking status, histologic type and S-CEA level that only S-CEA levels qualified as an independent predictive factor for distant metastases (p=0.001).Conclusion: We conclude that S-CEA levels were significant for predicting distant metastases. High levels of S-CEA may be an indication to perform routine investigation of distant metastases even in the absence of symptoms and signs.

show abstract

Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease

Cited by 149 publications

References 9 publications

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

Case Report Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment

Serum Carcinoembryonic Antigen Level as a Predictive Marker for Distant Metastasis in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About